Lexicon Cuts Commercial Operation, Focuses On R&D After FDA Letdown

Pipeline Includes Neuropathic Pain, Cardiomyopathy, Obesity

 
• By Mandy Jackson
  
Lexicon's restructuring plan represents its second round of layoffs this year. (Shutterstock)
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Financing

More from Scrip